Bruce E Sands1, Jean-Frédéric Colombel1, Christina Ha2, Michel Farnier3, Alessandro Armuzzi4, Daniel Quirk5, Gary S Friedman5, Kenneth Kwok6, Leonardo Salese5, Chinyu Su5, Pam R Taub7. 1. Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 2. Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California, USA. 3. PEC2, EA 7460, University of Bourgogne-Franche Comté and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France. 4. IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 5. Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA. 6. Inflammation & Immunology, Pfizer Inc, New York, New York, USA. 7. Division of Cardiovascular Medicine, University of California, San Diego, California, USA.
Abstract
BACKGROUND: Patients with ulcerative colitis (UC) are at elevated risk of cardiovascular disease vs the general population, despite a lower prevalence of traditional risk factors, including hyperlipidemia. Mechanistic studies in patients with rheumatoid arthritis and psoriasis suggest that tofacitinib restores serum lipids to preinflammation levels by reversing inflammation-induced cholesterol metabolism changes. We reviewed data on lipid levels and cardiovascular events, alongside recommendations for managing lipid levels during tofacitinib treatment in patients with UC, based on up-to-date expert guidelines. METHODS: Data were identified from a phase 3/open-label, long-term extension (OLE) tofacitinib UC clinical program (cutoff May 27, 2019). Literature was identified from PubMed (search terms "lipid," "cholesterol," "lipoprotein," "cardiovascular," "inflammation," "atherosclerosis," "tofacitinib," "rheumatoid arthritis," "psoriasis," "inflammatory bowel disease," "ulcerative colitis," "hyperlipidemia," and "guidelines") and author knowledge. Data were available from 4 phase 3 clinical trials of 1124 patients with moderately to severely active UC who received ≥1 dose of tofacitinib 5 or 10 mg twice daily in induction (two identical trials), maintenance, and OLE studies (treatment duration ≤6.8 years; 2576.4 patient-years of drug exposure). RESULTS: In the OLE study, tofacitinib treatment was not associated with major changes from baseline in total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, total cholesterol/high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol, with lipid levels and ratios generally remaining stable over time. The major adverse cardiovascular events incidence rate was 0.26/100 patient-years (95% confidence interval, 0.11-0.54). CONCLUSIONS: Lipid levels and ratios remained generally unchanged from baseline in the OLE study after tofacitinib treatment, and major adverse cardiovascular events were infrequent. Long-term studies are ongoing. CLINICALTRIALS.GOV IDENTIFIERS: NCT01465763, NCT01458951, NCT01458574, NCT01470612.
BACKGROUND: Patients with ulcerative colitis (UC) are at elevated risk of cardiovascular disease vs the general population, despite a lower prevalence of traditional risk factors, including hyperlipidemia. Mechanistic studies in patients with rheumatoid arthritis and psoriasis suggest that tofacitinib restores serum lipids to preinflammation levels by reversing inflammation-induced cholesterol metabolism changes. We reviewed data on lipid levels and cardiovascular events, alongside recommendations for managing lipid levels during tofacitinib treatment in patients with UC, based on up-to-date expert guidelines. METHODS: Data were identified from a phase 3/open-label, long-term extension (OLE) tofacitinib UC clinical program (cutoff May 27, 2019). Literature was identified from PubMed (search terms "lipid," "cholesterol," "lipoprotein," "cardiovascular," "inflammation," "atherosclerosis," "tofacitinib," "rheumatoid arthritis," "psoriasis," "inflammatory bowel disease," "ulcerative colitis," "hyperlipidemia," and "guidelines") and author knowledge. Data were available from 4 phase 3 clinical trials of 1124 patients with moderately to severely active UC who received ≥1 dose of tofacitinib 5 or 10 mg twice daily in induction (two identical trials), maintenance, and OLE studies (treatment duration ≤6.8 years; 2576.4 patient-years of drug exposure). RESULTS: In the OLE study, tofacitinib treatment was not associated with major changes from baseline in total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, total cholesterol/high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol, with lipid levels and ratios generally remaining stable over time. The major adverse cardiovascular events incidence rate was 0.26/100 patient-years (95% confidence interval, 0.11-0.54). CONCLUSIONS: Lipid levels and ratios remained generally unchanged from baseline in the OLE study after tofacitinib treatment, and major adverse cardiovascular events were infrequent. Long-term studies are ongoing. CLINICALTRIALS.GOV IDENTIFIERS: NCT01465763, NCT01458951, NCT01458574, NCT01470612.
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Katherine P Liao; Isaac Kohane Journal: Clin Gastroenterol Hepatol Date: 2016-02-22 Impact factor: 11.382
Authors: Jose Miguel Baena-Díez; Maria Garcia-Gil; Marc Comas-Cufí; Rafel Ramos; Daniel Prieto-Alhambra; Betlem Salvador-González; Roberto Elosua; Irene R Dégano; Judith Peñafiel; María Grau Journal: Heart Date: 2017-08-28 Impact factor: 5.994
Authors: Bruce E Sands; Pam R Taub; Alessandro Armuzzi; Gary S Friedman; Michele Moscariello; Nervin Lawendy; Ronald D Pedersen; Gary Chan; Chudy I Nduaka; Daniel Quirk; Leonardo Salese; Chinyu Su; Brian G Feagan Journal: Clin Gastroenterol Hepatol Date: 2019-05-08 Impact factor: 11.382
Authors: William J Sandborn; Chinyu Su; Bruce E Sands; Geert R D'Haens; Séverine Vermeire; Stefan Schreiber; Silvio Danese; Brian G Feagan; Walter Reinisch; Wojciech Niezychowski; Gary Friedman; Nervin Lawendy; Dahong Yu; Deborah Woodworth; Arnab Mukherjee; Haiying Zhang; Paul Healey; Julian Panés Journal: N Engl J Med Date: 2017-05-04 Impact factor: 91.245
Authors: Jesús Millán; Xavier Pintó; Anna Muñoz; Manuel Zúñiga; Joan Rubiés-Prat; Luis Felipe Pallardo; Luis Masana; Alipio Mangas; Antonio Hernández-Mijares; Pedro González-Santos; Juan F Ascaso; Juan Pedro-Botet Journal: Vasc Health Risk Manag Date: 2009-09-18
Authors: Cem Gabay; Iain B McInnes; Arthur Kavanaugh; Katie Tuckwell; Micki Klearman; Jennifer Pulley; Naveed Sattar Journal: Ann Rheum Dis Date: 2015-11-27 Impact factor: 19.103
Authors: Jasmijn A M Sleutjes; Jeanine E Roeters van Lennep; Eric Boersma; Luis A Menchen; Matthias Laudes; Klaudia Farkas; Tamás Molnár; Nicholas Alexander Kennedy; Marieke J Pierik; C Janneke van der Woude; Annemarie C de Vries Journal: Aliment Pharmacol Ther Date: 2021-08-28 Impact factor: 9.524